Filter
476
Featured
57
20
Language
Document type
130
128
54
48
32
28
18
8
6
5
5
3
2
1
Countries / Regions
26
26
13
12
9
8
6
5
5
4
4
4
4
3
3
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
71
34
12
8
6
6
6
6
5
5
4
4
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Toolboxes
26
23
22
22
19
19
17
17
17
17
16
16
16
16
15
15
13
13
13
13
12
12
12
11
11
11
11
11
11
11
11
10
10
10
9
9
9
9
9
9
8
8
8
8
8
7
7
7
7
7
6
6
6
6
6
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
If baby HIV exposed, do DBS at six weeks or any time the child is seen if still below 12 months. If > 12 months, do HIV antibody test.
A job aid for cadres supporting caregivers of children and adolescents living with HIV (ages 0-14) in Orphans and Vulnerable Children (OVC) Programs
JAMA. 2025;333(7):609–628. doi:10.1001/jama.2024.24543
Presentation Slides
Progress report and road map. Countries included in this report: Algeria, Afghanistan, Bahrain, Djibouti, Egypt, the Islamic Republic of Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Pakistan, Qatar, State of Palestine, Saudi Arabia, Somalia, Sudan, the Syrian Arab Republic, Tunisia, Un
...
Right to Care mini flipster
The emergence of high-level dolutegravir resistance was extremely rare in people switched to first-line dolutegravir-based treatment in Zambia and Malawi, a large prospective study has found.
Through the “Fiji National HIV Surge Strategic Plan 2024-2027,” the ministry will address areas for
Prevention, Diagnostics, Treatment and Care, the Continuum of Care and an intense Monitoring,
Evaluation, Accountability and Learning Framework for the government. This strategic plan aims
to d
...
Advanced Clinical Care (ACC) Live Tutorial session 22 August 2024
These online courses are based on the 2023 WHO Guidance for national strategic planning (NSP) and Guide for conducting programme reviews and are aligned with the Global health sector strategies on HIV, viral hepatitis, and STIs 2022–2030. These are designed to support countries in developing their
...
This video, created in collaboration with our Horizon Infectious Disease specialists, explores the fundamentals of human immunodeficiency virus (HIV) & acquired immunodeficiency syndrome (AIDS).
From transmission to treatment, this video provides concise, accurate information on diagnosis, early
...
The comic follows the story of Tiwale, a young girl from Malawi with dreams of becoming a football player. As she discovers that she is living with HIV, she learns to overcome her challenges with the support of her family and friends. This project investigates how the comic book is received by young
...
Pregnancy and childbirth during adolescence profoundly affects the lives of millions of girls worldwide, and is a leading cause of maternal mortality and morbidity, and infant and child mortality. Every year, an estimated 21 million girls aged 15–19 years old in low- and middle-income countries be
...
PARTICIPANT GUIDE.
This Participant Guide has been designed to assist health facilities and community based non-clinicians to develop skills to provide linkage to care, adherence and retention in care services for chronic conditions
Epidemiology
Chagas disease (American trypanosomiasis) is caused by the protozoan parasite Trypanosoma cruzi, and transmitted to humans by infected triatomine bugs, and less commonly by transfusion, organ transplant, from mother to infant, and in rare instances, by ingestion of contaminated food or
...
Countries are making progress toward the global goal of 95% of people living with HIV knowing their status by 2025. However, considerable gaps remain in achieving these goals globally. Men in high HIV burden settings and men from key populations in all settings are consistently less likely to know t
...
Les pays progressent vers la réalisation de l’objectif mondial tendant à ce que, d’ici 2025, 95 pour cent des personnes qui vivent avec le VIH connaissent leur statut sérologique. Cependant, en 2020, on estimait encore à 6 millions le nombre de personnes séropositives non diagnostiquées da
...
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les populations sous TAR. Bien que la résistance au DTG
...
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este antirretrovírico en las poblaciones tratadas con esquemas que lo contien
...
